Affimed N.V. (LON:0HL9)
1.010
-0.009 (-0.88%)
Feb 21, 2025, 4:37 PM BST
Affimed Revenue
Affimed had revenue of 164.00K EUR in the quarter ending September 30, 2024, a decrease of -91.62%. This brings the company's revenue in the last twelve months to 5.64M, down -72.92% year-over-year. In the year 2023, Affimed had annual revenue of 13.91M, down -67.39%.
Revenue (ttm)
5.64M EUR
Revenue Growth
-72.92%
P/S Ratio
n/a
Revenue / Employee
74.17K EUR
Employees
76
Market Cap
13.49M GBP
Revenue Chart
* This company reports financials in EUR.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 13.91M | -28.76M | -67.39% |
Dec 31, 2022 | 42.67M | 1.12M | 2.70% |
Dec 31, 2021 | 41.55M | 12.69M | 43.99% |
Dec 31, 2020 | 28.86M | 7.43M | 34.66% |
Dec 31, 2019 | 21.43M | -2.30M | -9.68% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 43.19B |
GSK plc | 31.38B |
Haleon | 11.24B |
Smith & Nephew | 4.46B |
Hikma Pharmaceuticals | 2.39B |
ConvaTec Group | 1.74B |
HUTCHMED (China) | 483.31M |
Oxford Nanopore Technologies | 167.75M |
Affimed News
- 2 months ago - Affimed Reports Positive Clinical Update on AFM24/Atezolizumab Combination Therapy in Non-Small Cell Lung Cancer (NSCLC) - Benzinga
- 2 months ago - Affimed Reports Promising Phase 1 Efficacy and Safety Data for AFM28 in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) - GlobeNewsWire
- 2 months ago - Affimed reports data from mid-stage study of its lymphoma treatment - Seeking Alpha
- 2 months ago - Affimed to Host Investor Conference Call Highlighting Clinical Data from AFM24 in Combination with Atezolizumab in Non-Small Cell Lung Cancer - GlobeNewsWire
- 2 months ago - Affimed Announces Positive Results Demonstrating Safety and Efficacy of Acimtamig and AlloNK® Combination in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) Patients - GlobeNewsWire
- 2 months ago - Affimed Announces Acimtamig and AlloNK® Combination Granted Regenerative Medicine Advanced Therapy (RMAT) Designation by the U.S. Food and Drug Administration (FDA) - GlobeNewsWire
- 3 months ago - Affimed N.V. (AFMD) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Affimed Reports Third Quarter 2024 Financial Results & Business Update - GlobeNewsWire